scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1068965770 |
P356 | DOI | 10.2119/MOLMED.2015.00139 |
P932 | PMC publication ID | 4559529 |
P698 | PubMed publication ID | 26070013 |
P5875 | ResearchGate publication ID | 278039323 |
P50 | author | Daniel S Lorrain | Q106171230 |
P2093 | author name string | David Spaner | |
Davorka Messmer | |||
Nicholas Chiorazzi | |||
Peppi Prasit | |||
Karin Stebbins | |||
Nicholas Stock | |||
Austin Chen | |||
Lucia Correa | |||
Yalda Bravo | |||
Geraldine Cabrera | |||
Jason Jacintho | |||
Kymmy Lorrain | |||
Xiao Jie Yan | |||
P2860 | cites work | A Mechanism-Driven Treatment for Chronic Lymphocytic Leukemia? | Q50894839 |
Fasting induces changes in peripheral blood mononuclear cell gene expression profiles related to increases in fatty acid beta-oxidation: functional role of peroxisome proliferator activated receptor alpha in human peripheral blood mononuclear cells | Q51460076 | ||
Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells | Q74357357 | ||
Identification of the first potent, selective and bioavailable PPARα antagonist | Q87709617 | ||
PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia | Q39243194 | ||
High levels of arachidonic acid and peroxisome proliferator-activated receptor-alpha in breast cancer tissues are associated with promoting cancer cell proliferation | Q39295543 | ||
Characterization of OP9 as authentic mesenchymal stem cell line | Q39675787 | ||
The phosphoinositide 3′-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. | Q40420056 | ||
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. | Q40710802 | ||
Cancer statistics, 1999. | Q40817780 | ||
Peroxisome proliferator-activated receptor alpha is an androgen-responsive gene in human prostate and is highly expressed in prostatic adenocarcinoma | Q40859311 | ||
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia | Q43119715 | ||
Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. | Q43120480 | ||
A PML–PPAR-δ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance | Q43195305 | ||
The triterpenoid CDDO induces apoptosis in refractory CLL B cells | Q44155427 | ||
Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. | Q46044632 | ||
Comprehensive analysis of PPARalpha-dependent regulation of hepatic lipid metabolism by expression profiling | Q21342976 | ||
An intronic peroxisome proliferator-activated receptor-binding sequence mediates fatty acid induction of the human carnitine palmitoyltransferase 1A | Q24293662 | ||
Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha | Q24319974 | ||
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia | Q24599100 | ||
Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment | Q26852398 | ||
Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents | Q27643634 | ||
On the Origin of Cancer Cells | Q27861025 | ||
On respiratory impairment in cancer cells | Q29617276 | ||
PPARalpha deficiency in inflammatory cells suppresses tumor growth | Q33275971 | ||
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction | Q33561797 | ||
In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells | Q33830733 | ||
Modeling tumor–host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy | Q34020276 | ||
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth | Q34147708 | ||
Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
Inhibition of PPARα Induces Cell Cycle Arrest and Apoptosis, and Synergizes with Glycolysis Inhibition in Kidney Cancer Cells | Q34948760 | ||
Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress | Q34976658 | ||
Treatment of fludarabine-refractory chronic lymphocytic leukemia | Q34978317 | ||
A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease | Q35029969 | ||
Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells | Q35777015 | ||
A metabolic prosurvival role for PML in breast cancer. | Q36208566 | ||
Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids | Q36895786 | ||
B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. | Q37028635 | ||
Cancer metabolism: fatty acid oxidation in the limelight | Q37155867 | ||
Molecular and cellular mechanisms of CLL: novel therapeutic approaches. | Q37504699 | ||
Adipocyte is a non-trivial, dynamic partner of breast cancer cells | Q37939013 | ||
Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators. | Q37977108 | ||
Non-glucose metabolism in cancer cells—is it all in the fat? | Q38019411 | ||
PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. | Q39132660 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 410-419 | |
P577 | publication date | 2015-06-09 | |
P1433 | published in | Molecular Medicine | Q6895961 |
P1476 | title | A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo | |
P478 | volume | 21 |
Q59810072 | A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells |
Q90075385 | Activation of β2-Adrenergic Receptor Promotes Growth and Angiogenesis in Breast Cancer by Down-regulating PPARγ |
Q47099331 | Alleviation of Toxicity Caused by Overactivation of Pparα through Pparα-Inducible miR-181a2. |
Q37096225 | PPAR-delta promotes survival of breast cancer cells in harsh metabolic conditions |
Q51219604 | PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions |
Q48471999 | PPARα Antagonist AA452 Triggers Metabolic Reprogramming and Increases Sensitivity to Radiation Therapy in Human Glioblastoma Primary Cells. |
Q64910634 | PPARα gene is a diagnostic and prognostic biomarker in clear cell renal cell carcinoma by integrated bioinformatics analysis. |
Q41694098 | Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy |
Q65002704 | Peroxisomes and Oxidative Stress: Their Implications in the Modulation of Cellular Immunity During Mycobacterial Infection. |
Q57785294 | Pparα deficiency inhibits the proliferation of neuronal and glial precursors in the zebrafish central nervous system |
Q48350605 | The Anticancer Potential of Peroxisome Proliferator-Activated Receptor Antagonists. |
Q59529106 | The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells |
Q57171912 | The Lipid Side of Bone Marrow Adipocytes: How Tumor Cells Adapt and Survive in Bone |
Search more.